About Prothelia

Prothelia is a Massachusetts based biopharmaceutical corporation focused on bringing therapeutics to patients suffering from muscular dystrophy. Our vision includes:

• Extending and improving the quality of life for affected individuals
• Working with leading academic institutions to identify and develop therapeutics
• Leveraging deep relationships with other pharmaceutical corporations and advocacy groups to speed product development and reduce product risk
• Partnering with regulatory agencies and clinicians to approve and run clinical trials
• Efficiently executing our business model to reduce investor risk and increase shareholder value

Please click on the links to the left for more details about Prothelia's management and scientific advisors, information for investors, or ways by which you can contact Prothelia.

Management

Rich Cloud, CEO

Prior to joining Prothelia Mr. Richard Cloud co-founded and was Chairman of Cure CMD, a non-profit corporation whose mission is finding a cure or treatment for those affected with Congenital Muscular Dystrophy. His responsibilities included leading the development and execution of a mission driven strategy including deploying an international CMD repository, establishing a research to clinical trial roadmap, fundraising, awareness and international collaboration with other Muscular Dystrophy organizations, pharmaceuticals and regulatory agency's. Mr. Cloud's background includes leadership roles within top tier Financial Services consulting firms, ownership of two businesses and U.S. Veteran. He holds an MBA (honors) from the University of Minnesota in Management Information Systems, Operations and Strategy. Mr. Cloud is active in church, educational committee's, national and international Muscular Dystrophy events and boards. His oldest daughter has Merosin Deficient Congenital Muscular Dystrophy.

Brad Hodges, PhD CSO

Bradley Hodges is the founder of Prothelia and has served as President and Chief Scientific Officer since 2007. Prior to starting Prothelia, Dr. Hodges was a scientist at Genzyme Corporation from 2000 to 2007. From 1998-2000 Dr. Hodges was a post-doctoral fellow at Duke University. Dr. Hodges received a PhD in cell and structural biology from the University of Illinois and a B.S. in Biology from Illinois State University.

Scientific And Medical Advisors

Dean J. Burkin, PhD

Dr. Burkin is Assistant Professor of Pharmacology and Director of the Nevada Transgenic Center at the University of Nevada School of Medicine, Reno NV. He received his PhD in Biochemistry from the University of Colorado, and performed postdoctoral fellowships at the University of Colorado and the University of Illinois. Dr. Burkin received a B.Sc. in Biology from Victoria University of Wellington, New Zealand.

Ed Connor, MD

Director, Office of Investigational Therapeutics at Children's National Medical Center and Professor of Pediatrics at George Washington University School of Medicine and Health Sciences.

Eric Hoffman, PhD

Chairman, Department of Integrative Systems Biology, George Washington University School of Medicine and Health Sciences and Director, Research Center for Genetic Medicine at Children's National Medical Center.

George J. Vella, PhD

Dr. Vella is the Director of Research and Strategic Planning for Charley's Fund, a philanthropic organization for DMD translational research. Dr. Vella received his PhD in Bio-Organic Chemistry from McMaster University, Hamilton, Canada and was a Post Doctoral Fellow in the Biochemistry Research Institute at the Hospital for Sick Children in Toronto, and later became a staff member in the Cardiovascular Research Focus Group at the same institution. Dr. Vella has 20 years of management experience including BioProcessors Corp., a VC backed start-up biotechnology company where he most recently served as Vice President of Research and Development. Prior to joining BioProcessors he was a Scientific Fellow at Applied Biosystems and held several positions during his six year tenure including Divisional Vice President of Science & Technology and Senior Director of Scientific Operations. He joined Applied Biosystems from PerSeptive Biosystems where he served as Vice President of Chemical R&D and later became Vice President of Technical Affairs. Prior to PerSeptive, Dr. Vella worked at Millipore and Waters in various senior managerial positions.

John M. McCall, PhD

President, PharMac LLC.

Markus A. Ruegg, PhD

Professor of Neurobiology, Biozentrum, University of Basel.

Stephen D. Hauschka, PhD

Dr. Hauschka is Professor of Biochemistry at the University of Washington. He received his PhD in Biology at Johns Hopkins and Carnegie Institution, and was a postdoctoral fellow at the University of Washington. Dr. Hauschka has over 40 years experience in the field of muscle biology and muscular dystrophy, and has been a member of numerous scientific panels and committees.

Close Management and Scientific Advisors

Endorsements by Scientists & Clinicians

Jim Collins, MD, PhD

Assistant Professor of Pediatric Neurology, University of Cincinnati College of Medicine, Pediatric Neurologist, Cincinnati Children's Hospital Medical Center.

Jim Dowling, MD, PhD

Assistant Professor, Division of Pediatric Neurology, Pediatric Neurologist, University of Michigan.

Kathy Mathews, MD

Director, Division of Pediatric Neurology, Development and Behavior Professor, Departments of Pediatrics and Neurology, University of Iowa Carver College of Medicine, University of Iowa Children's Hospital.

Xiao Xiao, PhD

Fred Eshelman Distinguished Professor of Gene Therapy, University of North Carolina, UNC Eshelman School of Pharmacy.

Brenda Wong, MD

Associate Professor of Clinical Pediatrics and Neurology Director, Pediatric Neuromuscular Program and MDA clinic, Cincinnati Children's Hospital Medical Center.

Close Endorsements by Scientists & Clinicians

Investor Information

Products for muscular dystrophy have many competitive features

• Orphan Drug Act protected markets
• Marketing and sales to a small numbers of specialists
• High barriers to competition
• Resistance to generic duplication
• Long product life cycle (>10 years)
• Our leaders are dedicated to improving the lives of patients with muscular dystrophy
• Prothelia's effort is focused exclusively on treating muscular dystrophy
• We have extensive experience in muscle biology and muscular dystrophy
• Our leaders have a record of publication in muscular dystrophy

The competition

All approved therapies for DMD and MDC1A are likely to be administered simultaneously minimizing the erosion of our market share from competitors. If approved each of our therapies will augment the therapeutic benefit of all other competing therapies.

Approach	Drug	% Responding DMD Patients	Disease / Indication	Company
Non-Dystrophin Functional Compensation	LAM-111	100	DMD / MDC1A / DCM	Prothelia
	PRT-300	100	DMD / MDC1A / DCM	Prothelia
	BMN 195	100	DMD	BioMarin
	Unnamed	100	DMD	PTC Therapeutics
	Biglycan	100	DMD	Tivorsan
Dystrophin mRNA Rescue	PTC124	~15	DMD / CF	PTC Therapeutics
	PRO-051	~15	DMD	Prosensa
	AVI-4658	~15	DMD	AVI BioPharma
Anti-apoptotic	PRT-20	100	DMD / MDC1A	Prothelia
	SNT-317	100	MDC1A	Santhera
Hypertrophic	ACE-031	100	Muscle loss	Acceleron
	rhIGF1	100	Myotonic MD	Insmed
Dystrophin Gene Replacement	Gene Therapy	100	DMD	Asklepios
	Stem Cells	100	DMD

Close Investor Information

Contact Information

Headquarters

Prothelia Incorporated
30 Haven Street
Milford, MA 01757
Fax: 508-276-0475
www.prothelia.com

Management

Rich Cloud, CEO
E-mail: rich.cloud@prothelia.com
Phone: 612-840-7106

Brad Hodges PhD, CSO
E-mail: bradhodges@prothelia.com
Phone: 508-561-9298

Close Contact Information